Conference Coverage
Oral Laquinimod Reduced MS Relapses by 23%
Major Finding: Patients taking the investigational oral drug laquinimod reduced their annualized rate of multiple sclerosis relapse by 23% after 2...
Dr. Kita said she has no relevant conflicts of interest. Dr. Greenberg disclosed financial relationships with DioGenix, Biogen Idec (which is developing BG-12), EMD Serono (which is developing cladribine), Teva Neurosciences (which is developing laquinimod), and the Greater Good Foundation.
Sanofi-Aventis, which is developing teriflunomide, funded the TEMSO trial. Dr. Miller, Dr. Wolinsky, and many of their associates in the study disclosed relationships with Sanofi-Aventis and with numerous other companies that make therapies for multiple sclerosis. Three of their co-investigators were employees of Sanofi-Aventis.